SCHEMBL5127683

SCHEMBL5127683

Cc1c(N)cccc1-c1cc(Nc2ccc(C(=O)N3CCN(C)CC3)cn2)c(=O)n(C)c1

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BTK Q06187 18/20 0.62
CLK2 P49760 1/20 0.54
HPGD P15428 1/20 0.44
FASN P49327 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4078372 0.92 BTK (0.73) BTKCLK2
SCHEMBL3963334 0.90 BTK (0.60) BTKCLK2HPGDFASN
SCHEMBL1322755 0.84 BTK (0.86) BTKCLK2
SCHEMBL12602983 0.83 BTK (0.75) BTKCLK2
SCHEMBL3963393 0.82 BTK (0.71) BTKCLK2
SCHEMBL3867754 0.81 BTK (0.74) BTKCLK2
SCHEMBL1323318 0.80 BTK (0.72) BTKCLK2
SCHEMBL171985 0.80 BTK (0.70) BTKCLK2
SCHEMBL1322002 0.80 BTK (0.71) BTKCLK2
SCHEMBL12650372 0.79 BTK (0.70) BTKCLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081923-B1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT INC (US) 2016-03-16 EP disclosed
US-20080139557-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139557-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, MYD88 BTK 1/4885CLK2 2498/4885HPGD 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.